Skip to content
Attgeno appoints Björn Westberg as CFO

Press release -

Attgeno appoints Björn Westberg as CFO

Attgeno AB announces today that Björn Westberg has been appointed CFO and member of the management team at Attgeno. Björn most recently comes from a role as CFO at Enea AB (publ).

Björn has extensive experience in the Life Science sector, where he has been active for 24 years in both small biotech and global pharmaceutical companies. In his previous roles as CFO, Björn has had four assignments in Nasdaq-listed companies, including Recipharm and Bonesupport, and has also led projects for listing on Nasdaq Stockholm. Björn's responsibilities in previous roles include finance, financing, investor relations, legal affairs, strategy development, HR and IT.

“I am very proud and happy to have been able to tie Björn to Attgeno. Through his solid background and international experience in Life Science, Attgeno receives an important contribution to further development into a successful pharmaceutical company. The Board and I both look forward to the continued work with Björn, which includes developing the company so that Attgeno's organization meets the requirements for listed companies, as a public listing is an alternative that may be relevant in the upcoming years.", says Per Agvald, Attgeno's co-founder and CEO.

Björn Westberg will take up the role of CFO in Attgeno in September 2021.

For further information, please contact

Per Agvald (MD, PhD), CEO

Telephone: +46 706 457 827

E-mail: per.agvald@attgeno.com

Christofer Adding (MD, PhD), CMO

Telephone: +46 707 886 766

E-mail: christofer.adding@attgeno.com

About Attgeno

Attgeno AB is a privately held Swedish biotech company devoted to development and commercialization of innovative and effective nitric oxide-donating drugs. Its leading drug candidate Supernitro (PDNO) is currently in early (phase I/IIa) clinical development. For further information, please visit www.attgeno.com.

About Supernitro (PDNO)

Supernitro is administered as an intravenous infusion, which upon entry into the blood, has an ultra-short half-life rapidly releasing its active moiety nitric oxide (NO). As a result, the majority of its NO is released just through the short passage through the lung blood circulation where it reacts with the blood vessels and causes them to dilate. The dilation reduces the resistance for the blood flow through the lungs generated by the pumping of the right heart, and thereby the lung blood pressure is decreased. With decreased pressure to work against the right heart is alleviated. By the donation of NO in the lungs, Supernitro replaces the decrease in NO production that is a well-known consequence of different diseases leading to increased risk for acute pulmonary hypertension.

About acute pulmonary hypertension

Acute pulmonary hypertension, due to acute elicited constriction of the vessels in the lung blood circulation, is a feared complication to major surgery, especially heart surgery, lung emboli and severe infections e.g., Covid-19. In acute pulmonary hypertension, constriction of blood vessels within the lung causes increased resistance in the lung blood vessels with a risk that the heart’s right ventricle does not have the capacity to sufficiently pump the blood through the lungs. In severe cases, the consequence is right heart failure and a drop in systemic blood pressure threatening blood flow to vital organs such as the brain, liver, kidneys and the heart itself – which can lead to a rapid death.

Related links

Subjects

Categories


About Attgeno

Attgeno AB is a privately held Swedish biotech company devoted to development and commercialization of innovative and effective nitric oxide-donating drugs. Its leading drug candidate Supernitro (PDNO) is currently in early (phase I/IIa) clinical development. For further information, please visit www.attgeno.com.

About Supernitro (PDNO)

Supernitro is administered as an intravenous infusion, which upon entry into the blood, has an ultra-short half-life rapidly releasing its active moiety nitric oxide (NO). As a result, the majority of its NO is released just through the short passage through the lung blood circulation where it reacts with the blood vessels and causes them to dilate. The dilation reduces the resistance for the blood flow through the lungs generated by the pumping of the right heart, and thereby the lung blood pressure is decreased. With decreased pressure to work against the right heart is alleviated. By the donation of NO in the lungs, Supernitro replaces the decrease in NO production that is a well-known consequence of different diseases leading to increased risk for acute pulmonary hypertension.

About acute pulmonary hypertension

Acute pulmonary hypertension, due to acute elicited constriction of the vessels in the lung blood circulation, is a feared complication to major surgery, especially heart surgery, lung emboli and severe infections e.g., Covid-19. In acute pulmonary hypertension, constriction of blood vessels within the lung causes increased resistance in the lung blood vessels with a risk that the heart’s right ventricle does not have the capacity to sufficiently pump the blood through the lungs. In severe cases, the consequence is right heart failure and a drop in systemic blood pressure threatening blood flow to vital organs such as the brain, liver, kidneys and the heart itself – which can lead to a rapid death.

Press contacts

Attgeno - develops new drug candidates for treatment of acute pulmonary hypertension using technology based on ground-breaking nitric oxide research

Attgeno is a Swedish, clinical stage, pharmaceutical company developing new, innovative and efficient nitric oxide-donating drugs. Our technology allows us to tailor drugs to release nitric oxide to specific organs in the body. Our primary goal bring our first drug candidate, Supernitro to the patients as a treatment for acute pulmonary hypertension, high pressure in the lung blood circulation, a life-threatening condition that occurs in a large number of different critical illnesses.

Attgeno
Fogdevreten 2A
171 65 Solna
Sverige
Visit our other newsrooms